CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC50 of 520 nM.
体内研究
CCT369260 (compound 1, 15 mg/kg, po, single dose) significantly inhibits BCL6 in OCI-Ly1 DLBCL xenograft model.
Animal Model:
OCI-Ly1 DLBCL xenograft model (female SCID mice).
Dosage:
15 mg/kg.
Administration:
PO, single dose.
Result:
Decreased the levels of BCL6 in the tumor observed up to 10 h after administration.
Animal Model:
Female Balb/C mice.
Dosage:
1 mg/kg iv and 5 mg/kg po (Pharmacokinetic Analysis).
Administration:
IV and PO
Result:
Demonstrated moderate clearance (CL 20 mL min kg) with mean oral bioavailability of 54%.
运输条件
Room temperature in continental US; may vary elsewhere.